Three major medical organizations have issued recommendations for the diagnosis and treatment of advanced prostate cancer, including metastatic hormone-sensitive disease and nonmetastatic and metastatic castration-resistant disease.
The FDA has granted accelerated approval to Rubraca for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy.
Investigators found that men treated with 5-alpha-reductase inhibitors are not more likely to die from prostate cancer or any other cause.
In a study, fathers who used intra-cytoplasmic sperm injection or in vitro fertilization had higher risk for prostate cancer than men who conceived naturally.
The Task Force recommends that for men 55 to 69 years of age, the decision to undergo prostate-specific antigen (PSA)-based screening for prostate cancer should be an individual one.
Erleada is the first FDA-approved therapy to treat patients with non-metastatic castration-resistant prostate cancer.
Screening for prostate cancer has long been part of the yearly checkup for many men. Although this procedure may reduce a patient’s risk for dying from the disease, evidence is conflicting about how helpful it actually is in reducing mortality. Because many prostate cancers are slow growing, treatment often does more psychological and physical harm…
